Neuropathic pain therapeutic - Sphaera Pharma/Synthia Dermatech

Drug Profile

Neuropathic pain therapeutic - Sphaera Pharma/Synthia Dermatech

Alternative Names: diclofenac sodium 1% + triclocarban

Latest Information Update: 13 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sphaera Pharma
  • Class Non-opioid analgesics
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Neuropathic pain

Most Recent Events

  • 13 Apr 2016 Clinical development is ongoing for Neuropathic pain in India
  • 31 Dec 2009 Sphaera Pharma enters into a collaboration with Synthia Dermatech for development of treatments for Neuropathic pain (Sphaera Pharma website, February 2016) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top